Bristol-Myers Squibb has announced plans to set up a biomanufacturing process laboratory in collaboration with Ireland's National Institute of Bioprocessing Research and Training (NIBRT).
Plasticell has teamed up with encapsulation and screening tech firm Sphere Fluidics to develop genetic modification technology for cell therapy production.
LeukoDx will develop a cell characterization system for GE Healthcare in a deal designed to bolster the latter’s cell therapy manufacturing technology offering.
Protein A is essential in keeping the costs and complexity of purifying monoclonal antibodies down, says GE Healthcare as it extends its supply agreement with Repligen.
Sartorius Stedim Biotech has launched a crossflow filtration system for scaling studies and low volume options normally available with process systems.
GE Healthcare has teamed up with the Canadian Government and the Toronto-based Centre for Commercialization of Regenerative Medicine develop cell therapy manufacturing technologies.
Protea Biosciences has teamed up with Agilent Technologies to offer drugmakers mass spectrometry alternatives to UV detection in QA/QC of recombinant proteins.
Analytical and downstream technology firm Waters has opened a subsidiary in Malaysia, citing the steady and consistent growth of biopharma in the region as a driver.
Takeda has taken a stake in Belgian bioprocessing start-up Univercells as part of a programme aimed at supplying low-cost vaccines to lower-income countries.
A single-use nanofibre-based purification technology could overcome limitations of current chromatography processes says Puridify, which has raised an additional £2.2m ($4m) in funding.
ABEC has begun supplying the Irish biopharma industry bioprocessing equipment from an ex-electronics facility in County Cork, acquired earlier this year.
Repligen could reap the financial rewards from two recently approved cholesterol-lowering proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors, a Jefferies analyst says.
Pfizer’s planned divestiture of its infliximab biosimilar candidate could create a race among competitors to gain access to the product, but in the early going, no clear leader has emerged.
Shire will use contractors to increase production of Cinryze, the half billion dollar-a-year Hereditary Angioedema (HAE) drug it bought with ViroPharma in 2014.
Sartorius finished the first half of 2015 with increased sales, higher operating profits and a surge in orders that prompted it to raise its full year forecast.
Agilent and A*STAR have partnered to create quicker, more accurate ways of testing the sugar content of therapeutic proteins and monoclonal antibodies (mAbs) that are tailored for commercial producers.
ReNeuron will automate processing of its stem cell-based stroke therapy ahead of planned Phase III trials using a system acquired from Sartorius Stedim Biotech (SSB) subsidiary, TAP Biosystems.
TxCell will enhance operator training and dedicate more resources to quality monitoring at the cell therapy facility where it halted production this week.
Small-scale production techs will dominate biopharma says the UK organisation tasked with developing the £20m “biologics factory of the future” and the £38m National Biologics Manufacturing Centre in Darlington.
EMA guidance on process validation for drugmakers is the latest update in cGMP regulations to manage a pharma world shifting from chemical to biological processing, says NNE Pharmaplan.
Pall has licensed a ‘filterless filter’ technology which developers FloDesignSonic says bridges the gap between the up and downstream in continuous bioprocessing.
Green Cross Biotherapeutics has begun constructing a facility in Canada it says will produce up to five tons of injectable antibodies and 25,000kg of albumin annually.
The adoption of new technologies related to single-use bioreactors, disposable plastic containers, continuous purification processing, and real-time quality analysis are driving the next generation of biomanufacturing, according to a new report from the...
Danaher's acquisition of Pall will not change the competitive landscape in the bioprocessing tech industry says Thermo Fisher, as it earmarks $10bn for further M&A activity.
The acquisition of Pall Corporation by either Thermo Fisher or Danaher could spur further M&A in the life science tech industry, according to an analyst.